RET kinase inhibitors
Disclosed herein are compounds of formula I:or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are...
Saved in:
Main Authors | , , , , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English |
Published |
11.07.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Disclosed herein are compounds of formula I:or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed. |
---|---|
AbstractList | Disclosed herein are compounds of formula I:or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed. |
Author | Pancaldi, Thomas Pierre Dino Boldron, Christopher Pierre Albert Jean Irvin, Thomas C McKenney, Megan L Pilkington-Miksa, Michael Alexander Kumar, Manoj McLean, Johnathan Alexander Munchhof, Michael J Anderson, Erin D Kolakowski, Gabrielle R Condroski, Kevin R McFaddin, Elizabeth A Mouret, Tiphaine Pinto, Marta Andrews, Steven W |
Author_xml | – fullname: Andrews, Steven W – fullname: McKenney, Megan L – fullname: Pancaldi, Thomas Pierre Dino – fullname: Irvin, Thomas C – fullname: McFaddin, Elizabeth A – fullname: Condroski, Kevin R – fullname: Pilkington-Miksa, Michael Alexander – fullname: Kolakowski, Gabrielle R – fullname: Anderson, Erin D – fullname: Mouret, Tiphaine – fullname: Munchhof, Michael J – fullname: Kumar, Manoj – fullname: Pinto, Marta – fullname: Boldron, Christopher Pierre Albert Jean – fullname: McLean, Johnathan Alexander |
BookMark | eNrjYmDJy89L5WQQDXINUcjOzEssTlXIzMvITMosyS8q5mFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8aHBhoZmluZmJuZORsbEqAEAJqci4Q |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
ExternalDocumentID | US11697647B2 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_US11697647B23 |
IEDL.DBID | EVB |
IngestDate | Fri Aug 09 05:01:10 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_US11697647B23 |
Notes | Application Number: US202117519878 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230711&DB=EPODOC&CC=US&NR=11697647B2 |
ParticipantIDs | epo_espacenet_US11697647B2 |
PublicationCentury | 2000 |
PublicationDate | 20230711 |
PublicationDateYYYYMMDD | 2023-07-11 |
PublicationDate_xml | – month: 07 year: 2023 text: 20230711 day: 11 |
PublicationDecade | 2020 |
PublicationYear | 2023 |
RelatedCompanies | Eli Lilly and Company |
RelatedCompanies_xml | – name: Eli Lilly and Company |
Score | 3.4768665 |
Snippet | Disclosed herein are compounds of formula I:or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | RET kinase inhibitors |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230711&DB=EPODOC&locale=&CC=US&NR=11697647B2 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LSwMxEB5KFfWmtaL1wQqyt8XuOz0swr4oQh-0u9JbSbZZGoW12BX_vpOwtV40p5DAkAx8800mMwnAA7dKlxKyMij6y4bjc8sYlIwbHnZNTgjzSlk7PBp7w9x5XriLFrzuamHUO6Ff6nFERFSBeK-Vvd7sg1ixyq3cPjKBQ-9PaRbEenM6llnNiN04DJLpJJ5EehQF-VwfzwLT9JB4HT9Ec32AbrQv0ZC8hLIqZfObUtJTOJyitKo-gxavOnAc7X5e68DRqLnwxm6Dve05dGdJpr2JCmlHE9VaMCE_yunCfZpk0dBA-cufzSzz-X4p9gW08ZDPL0EbEI9bLmGEUgdbSW2LFLx0Cnvl-n3av4Le33J6_01ew4lUjIxHmuYNtOuPT36LRFqzO6WBb01Tdpw |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebzombXxWkb8X1O3soQr-ounZja2VvI-1SrEIdruK_76V0zhfNU0jgSA5-97tc7hKAW6bkOiVkJVH0lyXNZIo0ylMmGdiVGSGpkfPa4TAygkR7XOiLFrxua2Hqd0K_6scREVEZ4r2q7fV6F8Ry69zKzV1a4ND7vR9brticjnlWM2LXtS1vOnEnjug4VjIXo5klywYSr2baaK730MU2ORq8Z5tXpax_U4p_BPtTlFZWx9BiZRc6zvbntS4chM2FN3Yb7G1OoDfzYuGtKJF2hKJ8KdKCf5TTgxvfi51AQvnLn80sk_luKeoptPGQz85AGBGDKTpJCaUatpyqCslYrmXqSjeHdNiHwd9yBv9NXkMniMPxcvwQPZ3DIVcSj03K8gW0q49PdomkWqVXtTa-AQedeY8 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=RET+kinase+inhibitors&rft.inventor=Andrews%2C+Steven+W&rft.inventor=McKenney%2C+Megan+L&rft.inventor=Pancaldi%2C+Thomas+Pierre+Dino&rft.inventor=Irvin%2C+Thomas+C&rft.inventor=McFaddin%2C+Elizabeth+A&rft.inventor=Condroski%2C+Kevin+R&rft.inventor=Pilkington-Miksa%2C+Michael+Alexander&rft.inventor=Kolakowski%2C+Gabrielle+R&rft.inventor=Anderson%2C+Erin+D&rft.inventor=Mouret%2C+Tiphaine&rft.inventor=Munchhof%2C+Michael+J&rft.inventor=Kumar%2C+Manoj&rft.inventor=Pinto%2C+Marta&rft.inventor=Boldron%2C+Christopher+Pierre+Albert+Jean&rft.inventor=McLean%2C+Johnathan+Alexander&rft.date=2023-07-11&rft.externalDBID=B2&rft.externalDocID=US11697647B2 |